Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression.
Patients with bipolar disorder are often prescribed lithium in combination with a selective serotonin reuptake inhibitor. Doubts still remain, however, about the safety of the combination, particularly with regard to the risk of developing a serotonin syndrome. The authors retrospectively evaluated the safety of the combination of lithium and paroxetine when the two medications were sequentially prescribed in patients with bipolar disorder. The authors examined a sample of 17 patients with bipolar disorder who were treated with lithium during a depressive episode and who required paroxetine as an adjunctive antidepressant to ongoing lithium treatment. Averaging across all subjects, no statistically significant increase was found for any of the somatic symptoms that were assessed before and after paroxetine was added to ongoing lithium therapy. Examining the clinical records of each patient in detail; however, four patients who developed significant adverse events, possibly related to an emerging serotonin syndrome were identified. Clinicians should be aware of the possible development of a serotonin syndrome among patients in whom paroxetine is added to ongoing lithium treatment.
Fagiolini
A
A
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pennsylvania 15213, USA. fagiolinia@msx.upmc.edu
Buysse
D J
DJ
Frank
E
E
Houck
P R
PR
Luther
J F
JF
Kupfer
D J
DJ
D000328:Adult; D001714:Bipolar Disorder / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003866:Depressive Disorder / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008094:Lithium / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D012189:Retrospective Studies; D020230:Serotonin Syndrome / Q000097:blood / Q000139:chemically induced*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use
D008094:Lithium; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors